Claims for Patent: 10,842,768

Summary for Patent: 10,842,768

Title:	Compositions and methods for lowering triglycerides
Abstract:	In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
Inventor(s):	Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT), Manku; Mehar (Birmingham, GB)
Assignee:	Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:	16/364,720
Patent Claims:	1. A method of lowering triglycerides and LDL-C in a subject comprising, administering orally to a subject having fasting triglycerides of about 200 mg/dl to less than 500 mg/dl who is on stable statin therapy about 4 g per day of a pharmaceutical composition comprising at least about 96%, by weight of all fatty acids present, ethyl eicosapentaenoate for a period of at least about 12 weeks to effect a reduction in fasting triglycerides and fasting LDL-C in the subject, wherein the stable statin therapy comprises administering about 10 mg to about 100 mg per day of a statin selected from atorvastatin, rosuvastatin and simvastatin. 2. The method of claim 1, comprising administering the composition to effect a reduction in fasting non-HDL-C. 3. The method of claim 1, comprising administering the composition to effect a reduction in fasting VLDL-C. 4. The method of claim 1, comprising administering the composition to effect a reduction in fasting Apolipoprotein B. 5. The method of claim 1, comprising administering the composition to effect a reduction in fasting total cholesterol. 6. A method of lowering triglycerides and LDL-C in a subject comprising, administering orally to a subject having fasting triglycerides from about 200 mg/dl to less than 500 mg/dl who is on stable statin therapy about 4 g per day of a pharmaceutical composition comprising at least about 96%, by weight of all fatty acids present, ethyl eicosapentaenoate for a period of at least about 12 weeks to effect a reduction in fasting triglycerides in the subject by least 5% and to effect a reduction in fasting LDL-C in the subject by at least about 5%, wherein the stable statin therapy comprises administering about 10 mg to about 100 mg per day of a statin selected from atorvastatin, rosuvastatin and simvastatin. 7. The method of claim 6, comprising administering the composition to effect at least a 5% reduction in fasting LDL-C. 8. A method of lowering triglycerides in a subject on stable statin therapy and having fasting a baseline triglyceride level from about 200 mg/dl to less than 500 mg/dl comprising administering orally to the subject about 4 g per day of a pharmaceutical composition comprising at least about 96%, by weight of all fatty acids present, ethyl eicosapentaenoate for a period of 12 weeks, which when administered to a first patient population on stable statin therapy and having said baseline triglyceride level at 4 g per day for twelve weeks is effective to reduce fasting triglycerides and fasting LDL-C, wherein the stable statin therapy comprises about 10 mg to about 100 mg per day of a statin selected from atorvastatin, rosuvastatin and simvastatin. 9. The method of claim 6, comprising administering the composition to effect a reduction in fasting non-HDL-C.